Thermo Fisher Scientific (NYSE:TMO) Receives "Hold (C)" Rating from Weiss Ratings

Key Points

• Weiss Ratings has reaffirmed a "Hold (C)" rating for Thermo Fisher Scientific (NYSE:TMO), indicating a cautious outlook from investment analysts.
• Several analysts have set varying price targets for TMO, with Royal Bank of Canada at $561, Evercore ISI at $590, and Robert W. Baird at $567, reflecting a consensus rating of "Moderate Buy."
• In recent insider activity, CEO Marc N. Casper sold 10,000 shares of TMO stock, which represents a 7.99% decrease in his ownership position.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report)'s stock had its "hold (c)" rating reaffirmed by investment analysts at Weiss Ratings in a report issued on Tuesday,Weiss Ratings reports.

A number of other equities research analysts have also issued reports on the company. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the stock an "outperform" rating in a research note on Tuesday, September 2nd. Evercore ISI raised their price objective on Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an "outperform" rating in a report on Tuesday, October 7th. Robert W. Baird raised their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. Wall Street Zen downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday. Finally, Redburn Partners set a $580.00 price objective on Thermo Fisher Scientific in a report on Wednesday, October 8th. Fifteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus price target of $589.10.

Thermo Fisher Scientific Trading Up 0.4%

Shares of TMO stock traded up $2.29 on Tuesday, reaching $526.87. 635,178 shares of the company's stock were exchanged, compared to its average volume of 2,416,658. Thermo Fisher Scientific has a 52 week low of $385.46 and a 52 week high of $610.97. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $198.95 billion, a PE ratio of 30.45, a P/E/G ratio of 2.85 and a beta of 0.77. The company's fifty day simple moving average is $489.83 and its 200 day simple moving average is $447.66.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same period last year, the company earned $5.37 EPS. Thermo Fisher Scientific's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, analysts forecast that Thermo Fisher Scientific will post 23.28 EPS for the current year.

Insider Activity

In related news, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the transaction, the chief executive officer owned 115,174 shares in the company, valued at approximately $57,697,567.04. This trade represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Brighton Jones LLC lifted its position in Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock worth $2,293,000 after acquiring an additional 988 shares during the period. Revolve Wealth Partners LLC lifted its position in Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after acquiring an additional 20 shares during the period. GAMMA Investing LLC lifted its position in Thermo Fisher Scientific by 22.0% during the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock worth $2,419,000 after acquiring an additional 877 shares during the period. Dynamic Advisor Solutions LLC acquired a new stake in Thermo Fisher Scientific during the 1st quarter worth about $2,218,000. Finally, Mission Wealth Management LP lifted its position in Thermo Fisher Scientific by 15.2% during the 1st quarter. Mission Wealth Management LP now owns 5,051 shares of the medical research company's stock worth $2,514,000 after acquiring an additional 668 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.